← Leaderboards
Jie Shen
University Of Connecticut Storrs
$2,263,620
Attributed
$2,928,122
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $996.8K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
FDA$2,928,122 · 4
By mechanism
U01$2,928,122 · 4
Top collaborators
- Diane Jane Burgess1 shared
- Bodhisattwa Chaudhuri1 shared
Grant awards (9)
In Vitro Based Approaches to Evaluate the Bioequivalence of Locally-Acting Rectal and Vaginal Semi-Solid Drug Products$250,000
U01 · FY2025 · FD · contact PI
Evaluation of Oral Modified-Release Tablets to Support the Approval of Additional Strengths$250,000
U01 · FY2024 · FD · contact PI
In Vitro Based Approaches to Evaluate the Bioequivalence of Locally-Acting Rectal and Vaginal Semi-Solid Drug Products$250,000
U01 · FY2024 · FD · contact PI
In Vitro Based Approaches to Evaluate the Bioequivalence of Locally-Acting Rectal and Vaginal Semi-Solid Drug Products$231,369
U01 · FY2023 · FD · contact PI
Evaluation of Oral Modified-Release Tablets to Support the Approval of Additional Strengths$200,000
U01 · FY2023 · FD · contact PI
In Vitro Based Approaches to Evaluate the Bioequivalence of Locally-Acting Rectal and Vaginal Semi-Solid Drug Products$250,000
U01 · FY2022 · FD · contact PI
BIOEQUIVALENCE CONSIDERATIONS OF TOPICAL RECTAL AND VAGINAL SUPPOSITORIES$250,000
U01 · FY2020 · FD · contact PI
BIOEQUIVALENCE CONSIDERATIONS OF TOPICAL RECTAL AND VAGINAL SUPPOSITORIES$250,000
U01 · FY2019 · FD · contact PI
A Continuous Manufacturing Platform for Complex Dosage Forms$996,753
U01 · FY2017 · FD